Vital Chemtech (VITAL)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• High promoter holding of 73.43% aligns owner interests
• Book value per share of ₹44.04 provides some asset backing
• Debt-to-equity of 0.71 is manageable at current levels
• Latest quarter sales of ₹65 Cr indicate ongoing revenue base

Concerns

• Profit growth down 41.56% and sales growth at -2.06%
• ROE of 3.35% and ROCE of 6.68% are far below acceptable levels
• Negative free cash flow and Piotroski F-Score of 3/9 point to weak financial health
• P/E of 39.03 is expensive for a company with declining earnings and no dividend

AI Analysis

When I look at Vital Chemtech, the first thing I ask is: what does this business earn on the capital it employs? The answer is not encouraging. Return on equity is just 3.35%, and return on capital employed is a mere 6.68%. For a specialty chemicals company, these figures suggest no meaningful pricing power or operational edge. The latest quarter tells the same story—₹65 crore in sales but only ₹1 crore in net profit. That is a razor-thin margin, and it explains why profit growth has collapsed by 41.56% while sales have slipped 2.06%. At a price of ₹63.74, the market is paying 39 times earnings for a company whose earnings are falling. Benjamin Graham would remind me that buying a shrinking earnings stream at a high multiple is a recipe for poor returns. The balance sheet is not terrible—debt-to-equity is 0.71 and book value is ₹44.04—but the return on that book value is far too low to justify a price-to-book of 1.45. Free cash flow is negative, and the Piotroski F-Score of 3/9 confirms weak financial health. On the positive side, promoter holding is high at 73.43%, which means the owners have skin in the game. But high ownership does not compensate for poor economics. With no dividend, no growth, and deteriorating fundamentals, this feels like a business that is standing still while the market prices it as if it were advancing. I would need to see a clear path to higher margins and positive cash flow before I could even consider this as an investment. For now, it fails my test of a quality business at a sensible price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer